{
    "clinical_study": {
        "@rank": "112747", 
        "acronym": "TasQ003", 
        "arm_group": [
            {
                "arm_group_label": "Tasquinimod", 
                "arm_group_type": "Experimental", 
                "description": "Main study: 1 capsule (0.25, 0.50 or 1 mg) daily, taken orally once a day with water and food (preferably the main evening meal)."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "1 capsule daily, taken orally once a day with water and food (preferably the main evening meal)."
            }
        ], 
        "brief_summary": {
            "textblock": "To confirm the effect of tasquinimod in delaying disease progression or death as compared\n      with placebo in chemo-na\u00efve patients with metastatic castrate-resistant prostate cancer\n      (mCRPC)."
        }, 
        "brief_title": "Study Of Tasquinimod In Asian Chemo-Na\u00efve Patients With Metastatic Castrate-Resistant Prostate Cancer", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Asian Chemo-na\u00efve Patients With Metastatic Castrate-resistant Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Asian male aged at least 20 years at the time of signing the informed consent form\n\n          -  Histologically confirmed diagnosis of adenocarcinoma of the prostate\n\n          -  Evidence of metastatic disease (bone and/or visceral), excluding node lesion only, on\n             radiographic examination, whether from bone scan (bone lesions) or other imaging\n             modality (computed tomography [CT] scan/magnetic resonance imaging [MRI])\n\n          -  Chemical or surgical castration verified by levels of serum testosterone \u226450 ng/dL\n             (1.75 nmol/L), Evidence of progressive disease after castration levels of\n             testosterone have been achieved\n\n        Exclusion Criteria:\n\n          -  Cytotoxic chemotherapy for the treatment of prostate cancer within 2 years prior to\n             the start of study treatment\n\n          -  Previous anticancer therapy using radiation, biologics or vaccines and including\n             sipuleucel-T (Provenge\u00ae) within 4 weeks prior to the start of study treatment and\n             abiraterone, TAK700 or MDV3100 within 2 weeks prior to the start of study treatment.\n             Before inclusion, abiraterone, TAK700 or MDV3100 related adverse effect must have\n             been resolved to NCI-CTCAE v4.03 Grade \u22641. If radiation therapy is applied after\n             Baseline scan, a new Baseline scan needs to be done at least 4 weeks after the\n             radiation therapy\n\n          -  Therapy with antiandrogens within 4 weeks (within 6 weeks for bicalutamide e.g.\n             Casodex\u00ae) prior to the start of study treatment\n\n          -  Concurrent use of other anticancer agents or treatments, with the exception of\n             ongoing treatment with luteinising hormone-releasing hormone agonists or antagonists,\n             denosumab (Prolia\u00ae) or bisphosphonate (e.g. zoledronic acid), which are allowed.\n             Ongoing treatment should be kept at a stable schedule; however, if medically\n             required, a change of dose, compound, or both is allowed\n\n          -  Prostate cancer pain that requires ongoing treatment with narcotic analgesics or\n             warrants the initiation of radio- or chemotherapy\n\n          -  Prostate-Specific Antigen (PSA) >100 ng/mL"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02057666", 
            "org_study_id": "8-55-58102-003"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tasquinimod", 
                "description": "A patient will initially receive 0.25 mg/day dose which will then be titrated through 0.5 mg/day (from Day 15) to a maximum of 1mg/day (from Day 29). If tolerability issues arise at 0.5 or 1 mg/day, patients will have their dose reduced to 0.25 or 0.5 mg/day, respectively.", 
                "intervention_name": "Tasquinimod", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo capsules are identical to tasquinimod capsules in appearance and excipients but exclude the active compound (tasquinimod), to be taken orally once a day with water and food (preferably the main evening meal).", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanchang", 
                        "country": "China"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shangai", 
                        "country": "China"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shantou", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Soochow", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wenzhou", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cheongju", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taichung", 
                        "country": "Taiwan"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taichung", 
                        "country": "Taiwan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan"
                    }
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "China", 
                "Korea, Republic of", 
                "Taiwan"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III, Randomised, Double-Blind, Placebo-Controlled Study Of Tasquinimod In Asian Chemo-Na\u00efve Patients With Metastatic Castrate-Resistant Prostate Cancer", 
        "overall_contact": {
            "email": "clinical.trials@ipsen.com", 
            "last_name": "Ipsen Recruitment Enquiries"
        }, 
        "overall_official": {
            "affiliation": "Ipsen", 
            "last_name": "Medical Director Uro-Oncology", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "China: Food and Drug Administration", 
                "Taiwan : Food and Drug Administration", 
                "South Korea: Korea Food and Drug Administration (KFDA)"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "PFS is defined as the time from the date of randomisation to the date of radiological progression (confirmed by the central imaging assessment) or death due to any cause.", 
            "measure": "Time to Radiological Progression-Free Survival [PFS]", 
            "safety_issue": "No", 
            "time_frame": "Every 3 months, up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02057666"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall survival is defined as the time from randomisation to death due to any cause", 
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "Every 3 months, up to 3 years"
            }, 
            {
                "description": "Symptomatic PFS, defined as the time from the date of randomisation to the date of appearance of pain (using pain visual analogue scale [VAS]) at a site with documented disease and analgesic use, or skeletal-related events, or death due to prostate cancer, whichever occurs first.", 
                "measure": "Time to Symptomatic PFS  based on local assessment", 
                "safety_issue": "No", 
                "time_frame": "Every 3 months, up to 3 years"
            }, 
            {
                "measure": "Time from randomisation to further treatment for prostate cancer.", 
                "safety_issue": "No", 
                "time_frame": "Every 3 months, up to 3 years"
            }, 
            {
                "description": "Quality of Life (QoL) measured by the Functional Assessment of Cancer Therapy Prostate Module (FACT-P) questionnaire and by the EuroQol 5-Dimension QoL Instrument (EQ-5D).", 
                "measure": "Quality of Life (QoL)", 
                "safety_issue": "No", 
                "time_frame": "Every 3 months, up to 3 years"
            }
        ], 
        "source": "Ipsen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ipsen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}